a new one.
All posts from Actionable news
JUNO: JUNO THERAPEUTICS Inc
18 Biggest Mid-Day Losers For Wednesday
Eli Lilly and Co
declined 10.7 percent to $67.87 after the company’s drug solanezumab failed to meet primary endpoint for the treatment of mild dementia due to Alzheimer's disease in a late-stage study.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.